What You Should Know:

你应该知道的：

–

–

PathAI

PathAI

, a provider of

，一家提供者

AI-powered

人工智能驱动的

pathology solutions, and

病理学解决方案，以及

Northwestern Medicine

西北医学中心

, Chicago’s premier integrated academic health system announced a strategic multi-year collaboration aimed at transforming pathology diagnostics through the power of

芝加哥领先的综合学术健康系统宣布了一项战略性的多年合作，旨在通过强大的力量转变病理诊断。

artificial intelligence (AI)

人工智能 (AI)

.

。

– The partnership will see Northwestern Medicine implement

- 该合作将使西北医学实施

PathAI’s AISight™

PathAI的AISight™

digital pathology image management system with the goal of driving efficiency and quality in its pathology operations. Beyond the technological deployment, the joint effort establishes a broad framework for joint research initiatives, clinical innovation programs, and the co-development of new AI-powered diagnostic tools intended to improve patient outcomes..

数字病理图像管理系统，旨在提高其病理操作的效率和质量。除了技术部署之外，此次合作还建立了一个广泛的框架，用于开展联合研究计划、临床创新项目以及共同开发新的AI驱动诊断工具，以改善患者预后。

Transforming Pathology Operations with the AISight™ Digital Platform

使用AISight™数字平台转变病理操作

A cornerstone of the collaboration is the deployment of PathAI’s AISight™ digital pathology platform across Northwestern Medicine. Northwestern Medicine’s team of 95 pathologists will begin utilizing AISight to review pathology cases, enabling enhanced capabilities such as remote case review across the health system’s 11 hospitals..

合作的基石是在西北医学中心全面部署PathAI的AISight™数字病理平台。西北医学中心由95名病理学家组成的团队将开始使用AISight来审查病理病例，从而增强诸如跨该卫生系统11家医院的远程病例审查等功能。

AISight’s cloud-native platform allows high-resolution pathology images to be analyzed using PathAI’s sophisticated machine learning algorithms. By streamlining case assignment, slide viewing, and analysis on a centralized system, the platform is expected to enhance workflow efficiency, enable seamless collaboration among Northwestern Medicine’s pathologists (including remote consultations), and help maintain high diagnostic quality and consistency..

AISight的云原生平台能够使用PathAI先进的机器学习算法分析高分辨率病理图像。通过在集中式系统上简化病例分配、切片查看和分析，该平台有望提升工作流程效率，促进西北医学中心病理学家之间的无缝协作（包括远程会诊），并有助于保持高水平的诊断质量和一致性。

A Multi-Faceted Collaboration: Driving Research, Innovation, and Co-Development

多方面合作：推动研究、创新与共同开发

The partnership extends beyond the implementation of the AISight™ platform into a comprehensive effort to advance the field of AI in pathology. Key components include:

该合作伙伴关系超越了AISight™平台的实施，致力于全面推动病理学领域的人工智能发展。关键组成部分包括：

Joint research projects in AI-powered pathology:

人工智能病理学联合研究项目：

Scientists from PathAI and pathology researchers from Northwestern Medicine will collaborate on studies to explore new applications of AI in digital pathology. This includes areas such as enhancing cancer detection, quantifying biomarkers, and discovering novel disease patterns.

PathAI 的科学家们将与西北医学院的病理学研究人员合作，开展探索人工智能在数字病理学中的新应用的研究。这包括增强癌症检测、量化生物标志物以及发现新的疾病模式等领域。

Clinical innovation initiatives:

临床创新举措：

The collaborators will pilot new AI tools within clinical settings at Northwestern Medicine, integrating AI-driven insights into routine pathology practice to improve diagnostic accuracy, operational efficiency, and overall patient care.

合作者们将在西北大学医学院的临床环境中试用新的人工智能工具，将人工智能驱动的洞察整合到常规病理实践中，以提高诊断准确性、运营效率和整体患者护理水平。

Co-development of new diagnostic algorithms:

新诊断算法的共同开发：

Pathologists from Northwestern Medicine will work closely with PathAI to develop and refine next-generation AI tools. This process will leverage real-world clinical data and feedback to create algorithms specifically tailored to address unmet medical needs.

西北医学的病理学家将与PathAI紧密合作，开发和完善下一代人工智能工具。这一过程将利用真实世界的临床数据和反馈，创建专门针对未满足医疗需求的算法。

“At PathAI, our mission is to advance medicine by improving the accuracy and efficiency of pathology through AI,” said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. “Collaborating with Northwestern Medicine allows us to bring this mission to life on a large scale. We are thrilled to collaborate with an institution at the forefront of clinical excellence to deploy AISight and jointly develop AI tools that could redefine diagnostic pathology and improve patient outcomes.”.

“在PathAI，我们的使命是通过人工智能提高病理学的准确性和效率来推动医学进步，”PathAI首席执行官兼联合创始人Andy Beck博士表示。“与西北医学合作使我们能够大规模实现这一使命。我们非常高兴能与一家处于临床卓越前沿的机构合作，部署AISight，并共同开发可能重新定义诊断病理学并改善患者预后的AI工具。”